Treatment of type 2 DM in combination w/ metformin or sulphonylurea in patients w/ insufficient glycaemic control despite maximal tolerated dose of monotherapy w/ metformin or sulphonylurea; in combination w/ metformin & sulphonylurea or thiazolidinedione in patients w/ insufficient glycaemic control despite dual therapy.
CHF, inflammatory bowel disease, diabetic gastroparesis, increased risk of pancreatitis, preexisting thyroid disease, risk of dehydration. Increased risk of hypoglycaemia w/ sulfonylurea. Hepatic impairment. Do not administer via IV or IM. May affect ability to drive or operate machinery. Childn <18 yr.
May decrease Cmax & delay tmax of paracetamol, atorvastatin & OCs (ethinylestradiol, levonorgestrel). May increase Cmax of griseofulvin. May reduce AUC, decrease Cmax & delay tmax of digoxin & lisinopril.
Manage Account
Change Password
Sign Out
